

What is Alzheimer's disease?

Alzheimer's disease (AD) targets the brain and can affect memory, thinking, judgement, and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. There are more than six million Americans living with Alzheimer's, and that number is projected to rise to nearly 13 million by 2050.

What is the difference between mild and moderate AD?

People living with mild Alzheimer's disease may function independently and perform daily tasks, but the symptoms of memory loss become more evident and noticeable to friends and family. This memory loss is gradual and can be seen as trouble remembering recent important events, forgetting familiar words, or the location of everyday objects.

People with moderate Alzheimer's disease generally require a greater level of care and attention. This stage is typically the longest and can last for many years. Trouble with memory is more severe and individuals may confuse words, forget personal history or even family members. They may show an increased impulse to wander and become lost.

Have questions about this research study?

Write them down here and ask the study team at your local site. Their contact information can be found below.

- 1 _____
- 2 _____
- 3 _____
- 4 _____
- 5 _____



rethinkALZ

JOIN A CLINICAL STUDY TO ADVANCE ALZHEIMER'S TREATMENT

RethinkALZ.com

844-331-7300

About the RethinkALZ Clinical Research Study

The RethinkALZ clinical research study is currently enrolling patients. The purpose of these trials is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer's disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition.

To be considered for the RethinkALZ research study, patients must:

- Be ages 50 to 87 years old
- Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer's disease
- Have a gradual change in memory for six months or more
- Have a family member or loved one who can be available as a study partner during the entire study
- Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection

Other criteria will apply.

Study Participation

The RethinkALZ trial is now open to qualifying participants. The trial lasts 52 weeks. If you enroll into this trial, you will receive either the oral study drug or placebo twice a day. A placebo looks like the study drug but has no impact on the person taking it. There is no cost to the patient to participate in the RethinkALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.



For more information and to see if you or your loved one pre-qualifies, visit RethinkALZ.com or call 844-331-7300.

Importance of Clinical Trials

Clinical trials are research studies in which people volunteer to help find answers to specific health questions. When carefully conducted, they are the safest and fastest way to find new treatments and ways to improve health.

Volunteers who participate in a study must agree to the rules and terms outlined in the protocol. Similarly, researchers, doctors, and other health professionals who manage clinical trials must follow strict rules set by the FDA. These rules make sure that those who agree to participate are treated as safely as possible.

For many people, taking part in a clinical trial is important because their participation helps increase the understanding of disease and how to treat them. Some other benefits to participation are:

- Active participation in your own health and healthcare
- Access to new investigational drugs and treatments
- Access to healthcare providers who specialize in the condition being studied
- Knowing that you may be helping others with the condition, as well as yourself

